AU2005266887B2 - Method of diagnosing, monitoring and treating pulmonary diseases - Google Patents

Method of diagnosing, monitoring and treating pulmonary diseases Download PDF

Info

Publication number
AU2005266887B2
AU2005266887B2 AU2005266887A AU2005266887A AU2005266887B2 AU 2005266887 B2 AU2005266887 B2 AU 2005266887B2 AU 2005266887 A AU2005266887 A AU 2005266887A AU 2005266887 A AU2005266887 A AU 2005266887A AU 2005266887 B2 AU2005266887 B2 AU 2005266887B2
Authority
AU
Australia
Prior art keywords
lung function
compound
difference
subject
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005266887A
Other languages
English (en)
Other versions
AU2005266887A1 (en
Inventor
Peter J. Barnes
Sergei A. Kharitonov
Amir Pelleg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
DUSKA SCIENT CO
Duska Scientific Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DUSKA SCIENT CO, Duska Scientific Co filed Critical DUSKA SCIENT CO
Publication of AU2005266887A1 publication Critical patent/AU2005266887A1/en
Application granted granted Critical
Publication of AU2005266887B2 publication Critical patent/AU2005266887B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AU2005266887A 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases Ceased AU2005266887B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59010104P 2004-07-22 2004-07-22
US60/590,101 2004-07-22
US66203305P 2005-03-15 2005-03-15
US60/662,033 2005-03-15
PCT/US2005/026884 WO2006012639A2 (en) 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases

Publications (2)

Publication Number Publication Date
AU2005266887A1 AU2005266887A1 (en) 2006-02-02
AU2005266887B2 true AU2005266887B2 (en) 2011-08-18

Family

ID=35786780

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005266887A Ceased AU2005266887B2 (en) 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases

Country Status (6)

Country Link
US (2) US20060029548A1 (OSRAM)
EP (1) EP1773405A4 (OSRAM)
JP (1) JP2008507368A (OSRAM)
AU (1) AU2005266887B2 (OSRAM)
CA (1) CA2573565A1 (OSRAM)
WO (1) WO2006012639A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101012926B1 (ko) * 2005-09-01 2011-02-09 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8632605B2 (en) 2008-09-12 2014-01-21 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
CN102395571B (zh) 2009-02-13 2015-12-16 盐野义制药株式会社 三嗪衍生物及含有该三嗪衍生物的药物组合物
WO2010099542A2 (en) * 2009-02-27 2010-09-02 Duska Scientific Co. Formulations of atp and analogas of atp
JP5809621B2 (ja) 2009-05-18 2015-11-11 ヌームアールエックス・インコーポレーテッド 患者の肺を治療するインプラント
US20130164386A1 (en) * 2010-06-17 2013-06-27 The Johns Hopkins University Targeting the Alpha3 Subnit of Na+-K+-ATPase for the Treatment of Cough with Sulfenamides
PL2604595T3 (pl) 2010-08-10 2016-09-30 Pochodna triazyny i związek farmaceutyczny, który ją zawiera i wykazuje aktywność przeciwbólową
JP6138044B2 (ja) * 2011-08-10 2017-05-31 国立大学法人富山大学 痺れ又は自発痛の評価方法及び薬物のスクリーニング方法
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
CR20160093A (es) 2013-08-23 2016-08-26 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
WO2015061790A2 (en) 2013-10-25 2015-04-30 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US11272864B2 (en) 2015-09-14 2022-03-15 Health Care Originals, Inc. Respiratory disease monitoring wearable apparatus
US11622716B2 (en) 2017-02-13 2023-04-11 Health Care Originals, Inc. Wearable physiological monitoring systems and methods
PT3355889T (pt) 2015-09-29 2023-04-26 Afferent Pharmaceuticals Inc Moduladores de recetores de diaminopirimidina p2x3 e p2x2/3 para utilização no tratamento da tosse
US11241579B2 (en) * 2016-04-22 2022-02-08 The Regents Of The University Of California Monitoring and modulation of parasympathetic nervous system
US10955269B2 (en) 2016-05-20 2021-03-23 Health Care Originals, Inc. Wearable apparatus
AU2019236244B2 (en) * 2018-03-15 2025-02-20 The Children's Medical Center Corporation Method for treating asthma or allergic disease
PL3862000T3 (pl) 2018-10-05 2024-03-18 Shionogi & Co., Ltd Lek na przewlekły kaszel
US12312327B2 (en) 2019-09-19 2025-05-27 Shionogi & Co., Ltd. Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122466A (en) * 1989-06-13 1992-06-16 North Carolina State University Ballistic transformation of conifers
JP3121827B2 (ja) * 1990-09-04 2001-01-09 メドコ・リサーチ・インコーポレイテッド アデノシンまたはそのリン酸化誘導体を活性成分とする気管支収縮性肺疾患の診断剤
GB9109063D0 (en) * 1991-04-26 1991-06-12 Ici Plc Modification of lignin synthesis in plants
US5527586A (en) * 1992-03-18 1996-06-18 Printron, Inc. Apparatus and method for depositing metal particles on a dielectric substrate
US5348616A (en) * 1993-05-03 1994-09-20 Motorola, Inc. Method for patterning a mold
FR2709666B1 (fr) * 1993-09-07 1995-10-13 Oreal Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
JPH10501122A (ja) * 1994-05-27 1998-02-03 グラクソ、グループ、リミテッド Ｐ▲下２ｘ▼レセプター（プリノセプターファミリー）
US5597613A (en) * 1994-12-30 1997-01-28 Honeywell Inc. Scale-up process for replicating large area diffractive optical elements
US6482742B1 (en) * 2000-07-18 2002-11-19 Stephen Y. Chou Fluid pressure imprint lithography
US6309580B1 (en) * 1995-11-15 2001-10-30 Regents Of The University Of Minnesota Release surfaces, particularly for use in nanoimprint lithography
US5874420A (en) * 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US6410718B1 (en) * 1996-09-11 2002-06-25 Genesis Research & Development Corporation Ltd. Materials and methods for the modification of plant lignin content
US6653528B1 (en) * 1996-09-11 2003-11-25 Genesis Research & Development Corporation Limited Pinus radiata nucleic acids encoding O-methyl transferase and methods for the modification of plant lignin content therewith
US6204434B1 (en) * 1996-09-11 2001-03-20 Genesis Research & Development Corporation Limited Materials and methods for the modification of plant lignin content
US5850020A (en) * 1996-09-11 1998-12-15 Genesis Research & Development Corporation, Ltd. Materials and method for the modification of plant lignin content
US5735985A (en) * 1996-11-15 1998-04-07 Eastman Kodak Company Method for micromolding ceramic structures
US6372724B1 (en) * 1997-03-25 2002-04-16 Duska Scientific Co. Modulation of human mast cell activation
US6225143B1 (en) * 1998-06-03 2001-05-01 Lsi Logic Corporation Flip-chip integrated circuit routing to I/O devices
US6110401A (en) * 1998-08-24 2000-08-29 Physical Optics Corporation Method and apparatus for replicating light shaping surface structures on a rigid substrate
US6190929B1 (en) * 1999-07-23 2001-02-20 Micron Technology, Inc. Methods of forming semiconductor devices and methods of forming field emission displays
US6517995B1 (en) * 1999-09-14 2003-02-11 Massachusetts Institute Of Technology Fabrication of finely featured devices by liquid embossing
AU2001234671B2 (en) * 2000-01-31 2006-05-18 Genaera Corporation Mucin synthesis inhibitors
US6387787B1 (en) * 2001-03-02 2002-05-14 Motorola, Inc. Lithographic template and method of formation and use
EP1392643B1 (en) * 2001-05-18 2005-09-14 Abbott Laboratories Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
US6716754B2 (en) * 2002-03-12 2004-04-06 Micron Technology, Inc. Methods of forming patterns and molds for semiconductor constructions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURRIE, G.P. ET AL, Journal of Asthma. 2004, vol. 41, no. 3, pages 247-258 *
PELEG, A. & SCHULMAN, E.S., American Journal of Therapeutics. 2002, vol. 9, no. 5, pages 454-464 *
RUTGERS, S.R. ET AL., European Respiratory Journal. 2000, vol. 16, no. 3, pages 486-490 *

Also Published As

Publication number Publication date
US20100286274A1 (en) 2010-11-11
JP2008507368A (ja) 2008-03-13
EP1773405A4 (en) 2011-10-05
CA2573565A1 (en) 2006-02-02
US20060029548A1 (en) 2006-02-09
AU2005266887A1 (en) 2006-02-02
WO2006012639A9 (en) 2006-03-16
WO2006012639A2 (en) 2006-02-02
WO2006012639A3 (en) 2006-06-22
EP1773405A2 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
US20100286274A1 (en) Methods of Diagnosing, Monitoring and Treating Pulmonary Diseases
Moskowitz et al. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms
Krishna et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma
Bonvini et al. Targeting TRP channels for chronic cough: from bench to bedside
Cerrina et al. Comparison of human bronchial muscle responses to histamine in vivo with histamine and isoproterenol agonists in vitro
Basoglu et al. Effects of aerosolized adenosine 5′-triphosphate in smokers and patients with COPD
Taylor et al. Airway reactivity in chronic obstructive pulmonary disease: failure of in vivo methacholine responsiveness to correlate with cholinergic, adrenergic, or nonadrenergic responses in vitro
Garthwaite et al. Synaptic activation of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors in the mossy fibre pathway in adult and immature rat cerebellar slices
Komai et al. Acetazolamide specifically inhibits lingual trigeminal nerve responses to carbon dioxide
Schmidt et al. Adenosinergic modulation of respiratory neurones and hypoxic responses in the anaesthetized cat.
Benson et al. Bronchial reactivity: interaction between vagal stimulation and inhaled histamine
Oh et al. Reflex regulation of airway sympathetic nerves in guinea‐pigs
Fujimura et al. Prostanoids and cough response to capsaicin in asthma and chronic bronchitis
Tung et al. Peripheral induction of burst firing in locus coeruleus neurons by nicotine mediated via excitatory amino acids
Chung Review series: chronic cough: future directions in chronic cough: mechanisms and antitussives
Enarson et al. Predictors of bronchial hyperexcitability in grainhandlers
Dong et al. Sensitivity of rat temporalis muscle afferent fibers to peripheral N-methyl-D-aspartate receptor activation
Katsuki et al. Effects of acetylcholine on hypoglossal and C4 nerve activity in brainstem-spinal cord preparations from newborn rat
Penn et al. Effects of inflammation and acute beta-agonist inhalation on beta 2-AR signaling in human airways
Inoue et al. Excitatory role of axon reflex in bradykinin-induced contraction of guinea pig tracheal smooth muscle
Wilson et al. Allergic lung inflammation affects central noradrenergic control of cholinergic outflow to the airways in ferrets
Morr Immunological release of histamine from human lung: II. Studies on acetylcholine and the anticholinergic agent ipratropium bromide
Morgan et al. Alveolar epithelial ion and fluid transport: prolonged isoproterenol infusion impairs the ability of 2-agonists to increase alveolar liquid clearance
Leader et al. Symptomatology, Pulmonary Function and Response, and T Lymphocyte β2‐Receptors During Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease
Ioka et al. Natural killer activity and its changes among participants in a smoking cessation intervention program-a prospective pilot study of 6 months' duration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired